臺灣博碩士論文加值系統

背景: B型肝炎為全球健康的危害，它可以造成急性肝炎，猛爆性肝衰竭，慢性肝炎與其相關的併發症 (包括肝硬化與肝細胞癌等)，全球約有三億五千萬人為慢性B型肝炎帶原者，每年約有一百萬人口因為B型肝炎的併發症而死亡，在慢性B型肝炎病毒長期的感染中，B型肝炎e抗原抗體的血清轉換一般而言代表著患者體內病毒的複製減少，病毒量與肝炎活性的下降，然而人類宿主因素對於自發性B型肝炎e抗原抗體的血清轉換的影響仍然不清楚，因此在本研究中探討宿主賀爾蒙與細胞激素的影響。
研究設計與方法: 我們的研究以前瞻性長期世代追蹤的設計探討在慢性B型肝炎病毒感染的自然史中，影響及預測B型肝炎病毒血清病毒量下降，肝功能指數ALT變化的趨式與自發性e抗原抗體血清轉換的宿主因子(包括男性賀爾蒙與細胞激素)，為釐清宿主的影響，我們在分析時均考量病毒基因型與血清病毒量的影響。
在男性賀爾蒙因素方面我們檢測了早期(10歲)，中期(15歲)與晚期(20歲)青春期男性慢性B型肝炎帶原者血清睪固酮的濃度與病毒量，並同時分析SRD5A2基因多樣性與雄性激素接受子CAG重覆的數目等因子對自發性B型肝炎e抗原抗體的血清轉換的影響。
在細胞激素方面我們檢測了五個Th1與Th2所屬細胞激素基因的十一個細胞激素單一核酸多樣性，分析患者於免疫耐受期，發炎期到非活性期血清細胞激素的濃度與病毒量，並探討對自發性B型肝炎e抗原抗體的血清轉換的影響，同時研究介白質十與十二在肝細胞內與其它細胞激素的關聯性及對病毒precore/core基因於免疫發炎期產生突變的影響。
結果: 在一系列的研究中我們探討宿主雄性賀爾蒙相關因素與細胞激素的基因型及表現型對於慢性B型肝炎病毒感染的影響，並發現較早發生青春期與SRD5A2基因型於男性的慢性帶原者可預測較明顯的血清病毒量下降與與自發性e抗原抗體血清轉換的發生，也觀察到在青春期與慢性B型肝炎的病程中免疫耐受期與發炎期轉化過程的關連性。同時，細胞激素中的介白質十(-1082 G/G基因型)與十二(-10993 C/G 基因型)較高產量的基因型與血清表現型亦為預測e抗原抗體血清轉換的重要免疫因子，於肝臟內介白質十與十二均與丙型干擾素的表現呈現正相關，尤其以介白質十為主要的預測因子，高產量的介白質十基因型更於免疫發炎期預測較高的B型肝炎病毒precore/core基因C2189A的突變率。該突變的發生顯著與血清B型肝炎病毒血清病毒量減少相關。慢性B型肝炎病毒感染的肝臟內丙型干擾素同時預測較高的免疫調節因子PD-1/PD-L1的表現與較低的furin表現。
討論: 本研究為慢性B型肝炎病毒感染的自然史中，對宿主在賀爾蒙與細胞激素的影響提出鮮明的證據。不同的宿主免疫壓力造成不同的病毒突變型態與病程，並可能於自發性e抗原抗體血清轉換的免疫調節機轉中，由細胞破壞途徑(cytolytic pathway)轉換為非細胞破壞途徑(non-cytolytic pathway)的過程中提供了新的資訊。同時也發現furin可能為丙型干擾素抑制B型肝炎病毒之非細胞破壞途徑(non-cytolytic pathway)的方法之一。

Background: Hepatitis B virus (HBV) is a global health hazard, which may cause acutehepatitis, fulminant hepatic failure, chronic hepatitis, liver cirrhosis, and even hepatocellular carcinoma. There are 350 million chronic HBV infected patients in the world, and annually 1 million patients died of complication associated with HBV. During the chronic course of HBV infection, HBeAg seroconversion generally indicates the decrease in viral replication and subsidence of disease activity. However, the role of host factors on the process of spontaneous HBeAg seroconversion is unclear. Thus, we aimed to elucidate the possible roles of hormone and cytokine on the complex immune process.
Study Design and Methods: This is a long-term prospective cohort study. To confirm the impacts of hormone, we investigated the serum testosterone levels and HBV viral load at early (10years), middle (15 years), and late (20years) puberty. We also checked the SRD5A2 V89L polymorphism and the CAG repeat number of androgen receptor exon-1. About the roles of cytokines, we checked 11 single nucleotide polymorphism located at 5 Th1 and Th2 cytokine gene (IL-2, IL-4, IL-10, IL-12β, IFN-γ), and the serum cytokine levels and viral load at immune tolerance phase, inflammatory/clearance phase, and post HBeAg-seroconversion inactive phase. We further investigated the association between IL-10 and IL-12 in the liver with HBV infection and the relationship with IFN-γ and possible downstream signals. The impact of different host immune stress (IL-10 genotype) on the mutation pattern of HBV precore/core gene was also done.
Results: Earlier onset of puberty and higher SRD5A2 enzyme activity were associated with more viral load decrement during the puberty period (10-20 years) and earlier spontaneous HBeAg seroconversion. IL-10 -1082 G/G genotype and IL-12β C/G genotype were associated with higher baseline IL-10 serum levels and HBcAg inducible IL-12 levels, and both predict earlier onset of spontaneous HBeAg seroconversion. Intrahepatic IL-10 and IL-12βmRNA levels were associated with IFN-γ expression, which associated with lower furin and higher PD-1/PD-L1 expression in subjects with chronic HBV infection at the inflammatory phase. G/G genotype of IL-10 -1082 also associated with higher C2189A mutation rate at the HBV precore/core gene, which is also associated with lower HBV viral load.
Discussion: This study provided some new evidence of the impacts of hormone and cytokine on the natural course of chronic HBV infection. We also demonstrated that, different host immune stress may associate with different HBV mutation pattern and clinical outcomes.

目 錄
口試委員會審定書 …………………………………………… i
誌謝 …………………………………………………………… ii
中文摘要 ……………………………………………………… iii
英文摘要 ……………………………………………………… v
目錄 …………………………………………………………… vii
圖目錄 ………………………………………………………… viii
表目錄 ………………………………………………………… ix
博士論文內容
第一章 緒論 …………………………………………………… 1
第二章 研究方法與材料 ……………………………………… 22
第三章 結果 …………………………………………………… 30
第四章 討論 …………………………………………………… 42
第五章 展望 …………………………………………………… 63
第六章 論文英文簡述 ………………………………………… 74
第七章 參考文獻 ……………………………………………… 106
第八章 圖表 …………………………………………………… 125
第九章 附錄 …………………………………………………… 161

References
1.Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, Kim YS, Park K, Kim DK, Moon YM. Association between Hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000; 31: 1371-3.
2.Almarri A, Batchlor JR. HLA and hepatitis B infection. Lancet 1994; 344: 1994-5.
3.Amaro MJ, Bartolome J, Carreno V. Hepatitis B virus X protein transactivates the inducible nitric oxide synthase promoter. Hepatology 1999; 29: 915-23.
4.Asagullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-94.
5.Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105: 94-8.
6.Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. The Lancet 1981; 2: 1129-33.
7.Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000; 25: 85-96.
8.Belnap DM, Watts NR, Conway JF, Cheng N, Stahl SJ, Wingfield PT, Steven AC. Diversity of core antigen epitopes of hepatitis B virus. Proc Natl Acad Sci USA 2003; 19: 10884-9.
9.Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997; 100: 503-13.
10.Bidwell J, Keen L, Gallagher G, , Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D''Alfonso S. Cytokine gene polymorphism in human disease: on-line database. Genes Immun 1999; 1: 3-19.
11.Bozkaya H, Bozdayi M, Turkyilmaz R, Sarioglu M, Cetinkaya H, Cinar K, Köse K, Yurdaydin C, Uzunalimoglu O. Circulating IL-2, IL-10 and TNF- in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepato-Gastroenterol 2000;47:1675-9.
12.Carlier D, Jean-Jean O, Fouillot N, Will H, Rossignol JM. Importance of the C terminus of the hepatitis B virus precore protein in secretion of HBe antigen. J General Virol 1995; 76: 1041-5.
13.Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M. A phase I/II study of recombinant interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000; 32: 317-24.
14.Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-43.
15.Chang MH, Sung JL, Lee CY, Chen CJ, Chen JS, Hsu HY, Lee PI, Chen DS. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989; 115: 385-90.
16.Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-9.
17.Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, Hsu YL, Chen DS. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e antigen seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998; 28: 915-22.
18.Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS; Taiwan Childhood Hepatoma Study Group. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284: 3040-2.
19.Chang MH. Natural history of hepatitis B virus infection in children J Gastroenterol Hepatolgoy 2000; Suppl: E 16-9
20.Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS; Taiwan Childhood HCC Study Group. Preventation of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005; 11: 7953-7.
21.Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007; 12: 160-7.
22.Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-55.
23.Chang MH. Hepatitis B Vaccination: Disease and Cancer Prevention-A Taiwanese Experience. Clin Liver Dis. 2010; 14: 521-30.
24.Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
25.Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
26.Chen DS, Hsu NH, Sung JL, Hsu ST, Kuo YT, Lo KJ, Shih YT. A mass vaccination program against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257: 2597-603.
27.Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-16.
28.Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. Seroepidemiology of hepatitis B virus infection in children. JAMA 1996; 276: 906-8.
29.Chen HL. Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chen DS, Chang MH. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004; 39: 58-63.
30.Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, Billaud JN, Milich DR. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005; 79: 3016-27.
31.Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J, Hughes J, Milich DR. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913-8.
32.Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
33.Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528-34.
34.Cheong JY, Cho SW, Hwang IL, Yoon SK, Lee JH, Park CS, Lee JE, Hahm KB, Kim JH. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-α gene promoter polymorphisms. J Gastroenterol Hepatol 2006; 21:1163-9.
35.Chittiprol S, Kumar AM, Shetty KT, Kumar HR, Satishchandra P, Rao RS, Ravi V, Desai A, Subbakrishna DK, Philip M, Satish KS, Kumar M. HIV-1 clade C infection and pregressive distribution in the relationship between cortisol, DHEAS and CD4 cell function: a two-year follow-up study. Clin Chim Acta 2009; 409: 4-10.
36.Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, Caggiula A. The epidemiology of plasma testosterone levels in middle aged men. Am J Epidemiol 1981; 114: 804-16.
37.Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49: S112-21.
38.Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90000-person Haimen city cohort: I. hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369-76.
39.Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008;48:759-69.
40.Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G. Clinical, virologic, and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
41.Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H. Androgen-induced hepatoma. The Lancet 1975;1:430-2.
42.Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G. Clinical, virologic, and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
43.Ferrando SJ, Rakin JG, Poretsky L. Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year. J Acquir Immune Defic Syndr 1999; 22: 146-54.
44.Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, Ferrari C. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-93.
45.Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
46.Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epideniol Biomarkers Prev 2002; 11: 1041-7.
47.Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci 1997; 94: 3320-3.
48.Gray A, Feldman HA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44: 671-84.
49.Guidotti LG, McClary H, Loudis JM, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the liver of transgenic mice. J Exp Med 2000; 191: 1247-52.
50.Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
51.Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
52.Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Löhr HF, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503-7.
53.Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, Chen PJ, Chen DS. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 770-6.
54.Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986; 18: 301-7.
55.Hsu HY, Chang MH, Hsieh KH, Lee CY, Li HH, Hwang LH, Chen PJ, Chen DS. Cellular Immune Response to Hepatitis B Core Antigen in Maternal-Infant Transmission of Hepatitis B Virus. Hepatology 1992;15:770-6.
56.Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface varients in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30: 1312-7.
57.Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after nationwide vaccination program in Taiwan. Gut 2004; 53: 1499-503.
58.Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. No increase of hepatitis B surface antigen mutant prevailing in a children and adolescent population fully covered by universal infant immunization. J Infect Dis 2010; 201: 1192-200.
59.Hsu HY, Tsai HY, Wu TC, Chiang CL, Ni YH, Chen PJ, Chang MH. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008; 28: 1288-97.
60.Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Pediatr Gastroenterol Nutr 1993; 16: 66-9.
61.Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8(+) T cell effector functions after antigen recognitation in the liver. Immunity 2005; 23: 53-6.
62.Ito K, Kim KH, Lok ASF, Tong S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. 2009; 83: 3507-17.
63.Jacob MH, da R Janner D, Jahn MP, Kucharski LC, Belló-Klein A, Ribeiro MF. Age-related effects of DHEA on peripheral markers of oxidative stress. Cell Biochem Funct 2010; 28: 52-7.
64.Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies varients in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Gnet 2009; 41: 591-5.
65.Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
66.Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001; 139: 349-52.
67.Kao JH. Hepatitis B virus genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-50
68.Kao JH, Chen DS. Global control of hepatitis B virus. Lancet Infect Dis 2002; 2: 395-403.
69.Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72: 363-9.
70.Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007; 37: S47-54.
71.Kao PC, Wu JF, Ni YH, Lin YT, Chen HL, Huey-Jen Hsu S, Hsu HY, Chang MH. Tumor necrosis factor-alpha promoter region polymorphisms affect the course of spontaneous HBsAg antigen clearance. Liver Int 2010; in press
72.Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 636-53.
73.Kenny AM, Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr 2010; 58: 1707-14.
74.Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 624-35.
75.Kock J, Nassal M, Deres K, Blum HE, von Weizsacker F. Hepatitis B virus nucleocapsids formed by carboxy-terminally mutated core proteins contain spliced viral genomes but lack full-size DNA. J Virol 2004; 78: 13812-8.
76.Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 157-169.
77.Kuhn R, Lohler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficit mice develop chronic enterocolitis. Cell 1993; 75: 263-74
78.Kutlu NO, Akinci A, Sonmezgoz E, Temel I, Evliyaoğlu E. The effects of androstenediol and dehydroepiandrosterone on the immune response to BCG at puberty. J Trop Pediatr 2003; 49: 181-5.
79.Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
80.Lai CL, Shouval D, Lok AS, Chang TT, Chenquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
81.Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
82.Laine S, Thouard A, Derancourt J, Kress M, Sitterlin D, Rossignol JM. In vitro and in vivo interactions between the hepatitis B virus protein P22 and the cellular protein gC1qR. J Virol 2003; 77: 12875-80.
83.Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Pegintrtferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95
84.Lau GK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alpha-2a (40kd) (PEGASYS) one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2006; 44: S23.
85.Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165: 2783-9.
86.Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, Graham BS, Johnson TR, Elias JA. Transgenic overexpression of interleukin(IL)-10 in the lung causes mucus metaplasia, tissue inflammation and airway remodeling via IL-13-dependent and –independent pathways. J Biol Chem 2002; 277: 35466-74.
87.Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 1143-50.
88.Lei RX, Shi H, Peng XM, Zhu YH, Cheng J, Chen GH. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology 2009; 50: 763-71.
89.Liaw YF, Gane E, Leung N, Zeusem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; GLOBE Study Group. 2-year GLOBE trail results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
90.Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e Antigen Seroconversion: A critical Event in Chronic Hepatitis B Virus Infection. Dig Dis Sci 2010; 55: 2727-34.
91.Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, Wasser S, Peter FJ, Tan T, Goode M, Rodrigo AG. Viral quasi-species evolution during hepatitis Be Antigen seroconversion. Gastroenterology 2007; 133: 951-8.
92.Lin TM, Chen CJ, Wu MM, Yang CS, Chen JS, Lin CC, Kwang TY, Hsu ST, Lin SY, Hsu LC. Hepatitis B virus markers in Chinese Twins. Anticancer Res 1989; 9: 737-42.
93.Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25: 1097-107.
94.Liu Z, Luo K, He H, Hou J. Hot-spot mutations in hepatitis B virus core gene: eliciting or evading immune clearance? J Viral Hepat 2005; 12: 146-53.
95.Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
96.Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
97.Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcón-Segovia D, Wijdenes J, Galanaud P, Emilie D. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-800.
98.Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostate steroid 5α reductase. Cancer Res 1997; 57: 1020-2.
99.Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
100.Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
101.Mauboussin JM, Mahamat A, Peyriere H, Rouanet I, Fabbro-Peray P, Daures JP, Vincent D. Low plasma levels of dehydroepiandrosterone sulfate in HIV-positive patients coinfected with hepatitis C virus. HIV Med 2004; 5: 151-7.
102.McHutchison JG, Giannelli G, Nyberg L, Blatt LM, Waite K, Mischkot P, Pianko S, Conrad A, Grint P. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res. 1999; 19: 1265-70.
103.McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, Schlimgen R, Lee E, Foster B, Flemming D, Prussin C, Fleisher TA, Boumpas DT. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001; 167: 4075-82.
104.McNaughton L, Puttagunta L, Martinez-Cuesta MA, Kneteman N, Mayers I, Moqbel R, Hamid Q, Radomski MW. Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acda Sci USA 2002; 99: 17161-6.
105.Messageot F, Carlier D, Rossignol JM. The C terminus of the hepatitis B virus e antigen precussor is required for a tunicamycin-sensitive step that promotes efficient secretion of the antigen. J Virol 1998; 273: 18594-8.
106.Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. J Biol Chem 2003;10:891-5.
107.Mhatre AN, Trifiro MA, Kaufman M, Kazemi-Esfarjani P, Figlewicz D, Rouleau G, Pinsky L. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular dystrophy. Nat Genet 1993; 5: 184-8.
108.Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-β1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005; 42: 505-510.
109.Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologus graft-versus-host (GvHD): interleukin 10 and interferon-γ may be critical mediators for the development of autologus GvHD. Blood 2002; 100: 2650-8.
110.Miyazoe S, Hamasaki K, Nakata K, Kajiya Y, Kitajima K, Nakao K, Daikoku M, Yatsuhashi H, Koga M, Yano M, Eguchi K. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-92.
111.Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. TRENDS in Immunology 2003; 24: 36-43.
112.Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, Scholmerich J, Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and-γ and mediates T cell apoptosis. J Hepatol 2006; 45: 520-8.
113.Ni YH, Chang MH, Hsu HY, Chen HL. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection. Hepatology 2000; 32: 124-8.
114.Ni YH, Chang MH, Hung LM, Chen HL, Hsu HY, Chiu TY, Cen DS. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-800.
115.Ni YH, Chang MH, Tsuei DJ. Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut 2003; 52: 122-5.
116.Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, Yeh SH, Jeng YM, Tsai KS, Chen DS. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 123: 1848-56.
117.Ni YH, Chang MH, Hsu HY, Tsuei DJ. Longitudinal study on mutation profiles of core promoter and precore regions of the hepatitis B virus genome in children. Pediatr Res 2004; 56: 396-9.
118.Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, Tsuei DJ, Chen DS. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132: 2340-5.
119.Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-93.
120.Ni YH, Chen DS. Hepatitis B vaccination in children: The Taiwan Experience. Pathol Biol (Paris) 2010; 58: 296-300.
121.Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2010 Sep 2. Online; 2011; in press
122.Ning B, Shih C. Nucleolar localization of human hepatitis B virus capsid protein. J Virol 2004; 78: 13653-68.
123.Nelson DR, Lauwers GY, Lau JY, Davis GL.. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial in interferon nonresponders. Gastroenterology 2000; 118:655-60.
124.Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapyin chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38: 859-68.
125.Nordenfelt E, Andren-Sandberg M. Dane particle-associated DNA polymerase and e antigen: relation to chronic hepatitis among carriers of hepatitis B surface antigen. J Infect Dis 1976; 134: 85-9.
126.Okazaki T, Honj T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 1: 1-12.
127.Paz-y-Mino C, Witte T, Robles P, Llumipanta W, Diaz M, Arevalo M. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Cancer Genet Cytogenet 2009; 189: 71-6.
128.Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963-70.
129.Pesu M, Watford WT, Wei L, Xu L, Fuss I, Strober W, Andersson J, Shevach EM, Quezado M, Bouladoux N, Roebroek A, Belkaid Y, Creemers J, O''Shea JJ. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008; 455: 246-50.
130.Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B, antiviral and immunological activity. Hepatology 2005; 42: 1028-36.
131.Pockros PJ, Patel K, O''Brien C, Tong M, Smith C, Rustgi V, Carithers RL, McHutchison JG, Olek E, Debruin MF. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology. 2003; 37: 1368-74.
132.Ribeiro F, Lopes RP, Nunes CP, Maito F, Bonorino C, Bauer ME. Dehydroepiandrosterone sulfate enhances IgG and interferon-gamma production during immunization to tuberculosis in young but not ages mice. Biogerontology 2007; 8: 209-20.
133.Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut 1999; 44: 759-764.
134.Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997; 99: 3025-33.
135.Sanders JL, Cappola AR, Arnold AM, Boudreau RM, Chaves PH, Robbins J, Cushman M, Newman AB. Concurrent change in dehydroeipandrosterone sulfate and functional performance in the oldest old: results from the cardiovascular health study all stars study. J Gerontol A Biol Sci Med Sci 2010; 65: 976-81.
136.Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papilloma-virus-specific CD8+ cytotoxic T lymphocytes. J Virol 2000; 74: 4729-37.
137.Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71: 345-53.
138.Schlicht HJ, Wasenauer G. The quaternary structure, antigenicity, and aggregational behavior of the secretory core protein of human hepatitis B virus are determined by its signal sequence. J Virol 1991; 65: 6817-25.
139.Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn’s disease. Crohn’s disease IL-10 cooperative study group. Gastroenterology 2000; 119: 1461-72.
140.Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22: 1027-33.
141.Solerte SB, Floravanti M, Vignati G. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in human via locally generated immunoreactive insulin-like growth factor I. J Clin Endocrinol Metab 1999; 84: 2360-7.
142.Song LH, Binh VQ, Duy DN, Kun JFJ, Bock TC, Kremsner PG. Serum cytokine profiles associated with clinical oresentation in Vietnamese infected with hepatitis B virus. J Clin Viral 2003; 28: 93-103.
143.Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-92.
144.Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology 2007; 365: 285-91.
145.Takakura M, Tokushige K, Matsushita N, Hashimoto E, Shiratori K. Possible involvement of cytokine gene polymorphisms in fulminant hepatitis. J Gastroenterol Hepatol 2007; 22: 1271-7.
146.Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998; 133: 374-7.
147.Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patients and viral characteristics: a systemic review of evidence. Hepatology 2009; 49: S85-95.
148.Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
149.Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332: 1065-9.
150.Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001; 52: 113-16.
151.Tong Y, Tong S, Zhao X, Wang J, Jun J, Park J, Wands J, Li J. Initiation of duck hepatitis B virus infection requires cleavage by a furin-like protein. J Virol 2010; 84: 4569-78.
152.Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76.
153.Tsai A, Kawai S, Kwei K, Gewaily D, Hutter A, Tong DR, Li J, Wands JR, Tong S. Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology 2009; 387: 364-72.
154.Tseng LH, Lin MT, Shau WY, Lin WC, Chang FY, Chien KL, Hansen JA, Chen DS, Chen PJ. Correlation of interleukine-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 2006; 67: 127-33.
155.Tseng YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989; five years after a mass hepatitis B vaccination program. J Med Virol 1991; 34: 96-9.
156.Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
157.van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-7.
158.Wang IJ, Chiang TH, Shih YF, Lu SC, Lin LL, Shieh JW, Wang TH, Samples JR, Hung PT. The association of single nucleotide polymorphisms in the MMP-9 genes with susceptibility to acute primary angle closure glaucoma in Taiwanese patients. Mol Vis 2006; 12: 1223-32.
159.Wu JF, Chen CH, Hsieh RP, Shih HH, Chen YH, Li CR, Chiang CY, Shau WY, Ni YH, Chen HL, Hsu HY, Chang MH. HLA typing associated with hepatitis B e antigen seroconversion in children with chronic hepatitis B virus infection: a prospective sibling cohort study in Taiwan. J Pediatr 2006; 148: 647-51.
160.Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, Chang MH. Serum levels of interleukin 10 and 12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 2010; 138:165-72.
161.Wu YF, Wang LY, Lee TD, Lin HH, Hu CT, Cheng ML, Lo SY. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J Med Virol 2004; 72: 17-25.
162.Wynne SA, Crowther RA, Leslie AGW. The crystal structure of human hepatitis B virus capsid. Mol Cell 1999; 3: 771-80.
163.Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
164.Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ; REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 1134-43.
165.Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari FV. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 2010; 107: 798-802.
166.Yang PM, Sung JL, Chen DS. HLA-A,B,C, and DR antigens in chronic hepatitis B virus infection. Hepatogastroenterol 1989; 36: 363-6.
167.Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS, Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41: 659-66.
168.Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, Chen PJ. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer 2007; 120: 1610-7.
169.Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
170.Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, Hsiao TJ, Lin SM, Lee SD, Chen PJ, Liu CJ, Chen CJ. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 2023-8.
171.Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001; 93: 1644-51.
172.Yuan TT, Sahu GK, Whitehead WE, Greenberg R, Shih C. The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol 1999; 73: 10122-8.
173.Zavaglia C, Bortolon C, Ferrioli G, Rho A, Mondazzi L, Bottelli R, Ghessi A, Gelosa F, Iamoni G, Ideo G. HLA typing in chronic type B, D and C hepatitis. J Hepatol 1996; 24: 658-65.
174.Zeuzem S, Hopf U, Carreno V, Diago M, Shiffman M, Grüne S, Dudley FJ, Rakhit A, Rittweger K, Yap SH, Koff RS, Thomas HC. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 1999; 29: 1280-7.
175.Zeuzem S, Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-8.
176.Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS, Zhang SY, Li BS, Wang HF, Wu H, Lau GK, Fu YX, Wang FS. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008;134:1938-49.
177.Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicenter, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.